# Alembic Pharmaceuticals share price today (Alembic Pharmaceuticals Ltd, NSE: APLLTD)

> Alembic Pharmaceuticals share price today: ₹906.70 at the NSE close on 4 November 2026, down 1.7% in a year. Alembic Pharmaceuticals (NSE: APLLTD) is worth ₹17,819 crore, trades at a P/E of 23.9 and has closed between ₹656.20 and ₹921.95 over the past 52 weeks. > Alembic Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +15.7% in a year while the price moved −1.7%. APLLTD · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: ₹906.70 (−1.7% in a year)
- P/E: 23.9× (higher than 51% of the last 11 years)
- Revenue (Jun 2026): ₹2,150 Cr (+25.7% on a year ago)
- Profit (Jun 2026): ₹172 Cr (+11.7% on a year ago)
- Operating margin: 15.0% (−1.0 points on a year ago)
- ROCE: 13%, FY26
- ROIC: 13.4%, against a 12.0% cost of capital: +1.4 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Alembic Pharmaceuticals share price today? Alembic Pharmaceuticals Ltd's share price was ₹906.70 at the close on 4 November 2026. It has been stalling near its high for 3 weeks. That is 11.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹656 and ₹922, and at that close it sat 94% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 23 weeks in a row. Over the last 11 years the share price moved +47% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Alembic Pharmaceuticals this quarter? Two changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) and highest quarterly revenue in 15 quarters. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹2,150 crore, +25.7% on a year earlier. 2. Highest quarterly revenue in 15 quarters Revenue of ₹2,150 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are Alembic Pharmaceuticals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Alembic Pharmaceuticals reported revenue of ₹2,150 crore, up 25.7% from ₹1,711 crore a year earlier, and a profit of ₹172 crore, up 11.7% from ₹154 crore. ### Alembic Pharmaceuticals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹2,150 crore | ₹1,711 crore | +25.7% |
| Profit | ₹172 crore | ₹154 crore | +11.7% |
| Earnings per share | ₹8.80 | ₹7.85 | +12.1% |
| Operating margin | 15.0% | 16.0% | −1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Alembic Pharmaceuticals' management discussed these results on a call held on 4 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Alembic Pharmaceuticals share price history? Alembic Pharmaceuticals closed at ₹906.70 on 4 November 2026, down 1.7% from ₹921.95 a year earlier (7 November 2025) and up 16.5% over five years. Its highest weekly close since March 2016 was ₹1,245.05 on 2 August 2024. ### Alembic Pharmaceuticals share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹797.85 | +13.6% |
| 1 month ago · 1 Oct 2026 | ₹815.25 | +11.2% |
| 6 months ago · 8 May 2026 | ₹787.05 | +15.2% |
| 1 year ago · 7 Nov 2025 | ₹921.95 | −1.7% |
| 3 years ago · 3 Nov 2023 | ₹727.45 | +24.6% |
| 5 years ago · 4 Nov 2021 | ₹778.05 | +16.5% |
| 10 years ago · 4 Nov 2016 | ₹656.45 | +38.1% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹616.65 | +47.0% |
| Highest weekly close since March 2016 · 2 Aug 2024 | ₹1,245.05 | −27.2% |
| Lowest weekly close since March 2016 · 1 Jun 2018 | ₹420.00 | +115.9% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹921.95 | −1.7% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹656.20 | +38.2% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Alembic Pharmaceuticals? 4 Nov 2026: Alembic Pharmaceuticals closed at ₹906.70, up 13.6% on the week and up 11.2% on the month. 4 Aug 2026: Alembic Pharmaceuticals held its results call for April to June 2026. ### Earlier

- 29 Jul 2026: ex-date for a dividend of ₹12 a share. - Results for April to June 2026: Revenue up 25.7% and profit up 11.7% on a year earlier. ## What dividend does Alembic Pharmaceuticals pay? Alembic Pharmaceuticals paid ₹12 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.32% at the ₹906.70 close on 4 November 2026. The last was a dividend of ₹12 a share, ex-date 29 July 2026. ### Alembic Pharmaceuticals dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 29 Jul 2026 | ₹12 | Dividend | same day |
| 29 Jul 2025 | ₹11 | Dividend | same day |
| 15 Jul 2024 | ₹11 | Dividend | same day |
| 28 Jul 2023 | ₹8 | Dividend | same day |
| 17 Aug 2022 | ₹10 | Interim | 18 Aug 2022 |
| 19 Jul 2021 | ₹14 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Alembic Pharmaceuticals Ltd paid out 35% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Alembic Pharmaceuticals management say on the latest results call? On the call for April to June 2026, held on 4 August 2026, Alembic Pharmaceuticals' management spoke about the quarter; the main points are below. Source: [the call transcript](https://files.tijorifinance.com/insight/india/6937/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 4 August 2026.)

## Which stock lists is Alembic Pharmaceuticals on? Alembic Pharmaceuticals is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 418](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 17822.618411982203](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Alembic Pharmaceuticals profitable? Alembic Pharmaceuticals Ltd earned ₹172 Cr of net profit in the Jun 2026 quarter, +11.7% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹671 Cr. Over 10 years profit has grown −0.7% a year on average. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned ₹154 Cr. For the full year, FY26 profit was ₹671 Cr (+15.3% on the year before). Why profit moved: revenue changed +25.7% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +14.1% and revenue +14.2%. Profit and revenue are moving at about the same pace. ## How much revenue does Alembic Pharmaceuticals make, and is it growing? Alembic Pharmaceuticals Ltd reported ₹2,150 Cr of revenue in the Jun 2026 quarter, +25.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 8.8% a year on average. The last full year, FY26, came in at ₹7,345 Cr. The last four reported quarters add to ₹7,784 Cr. FY26 revenue was ₹7,345 Cr, +10.1% on the year before. Recent pace: the last four quarters grew +14.2% on average, against 8.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.1%, against +11.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +14.6%, against +4.7% a year (accelerating). ## How much of every ₹100 of sales does Alembic Pharmaceuticals keep? Alembic Pharmaceuticals Ltd's operating margin was 15.0% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 12.0% and 32.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.0 percentage points on the year while gross margin changed −5.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Alembic Pharmaceuticals' profit turning into cash? Over the last 3 years, 90% of Alembic Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹783 Cr of operating cash against ₹671 Cr of profit. After ₹722 Cr of spending on assets, ₹61.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 90% of profit came in as cash: the cash cycle got 120 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building. ## Where does Alembic Pharmaceuticals' cash go? Alembic Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 381 days in FY26, up from 261 days in FY21. It spent ₹1,636 Cr on assets over the last 3 years. Customers take 73 days to pay, and stock sits for 462 days on average. At FY26 sales of ₹7,345 Cr, each day of that cycle ties up about ₹20.1 Cr, so roughly ₹7,667 Cr is tied up in the business at any time. FY26: customers took 73 days to pay and stock sat for 462 days, about 15.2 months of sales sitting as stock, for a full cycle of 381 days, longer than FY21's 261. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 462 days. Customers pay about 73 days after that. Suppliers are paid at 154 days. Together that makes the 381-day cycle. Spending on assets: ₹1,636 Cr over the last 3 years, against ₹871 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹683 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Alembic Pharmaceuticals' P/E ratio, and how does it compare with its own history? Alembic Pharmaceuticals Ltd's P/E is 23.9×, in the middle of its own history: higher than 51% of past readings. Its usual P/E (the middle reading) is 23.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹35.27. Why the multiple is where it is: over the past year earnings per share moved +15.7% while the price moved −1.7%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +3.1% a year; about −6.4% a year came from earnings growth and about +9.5 percentage points from the multiple (the market paying more); over 10 years the price moved +3.3% a year; about +2.1% a year came from earnings growth and about +1.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Alembic Pharmaceuticals business getting better or worse? Alembic Pharmaceuticals Ltd's business is turning around. Profit growth has swung from −4.4% at its low to +14.6%, rising from a low 4 quarters ago, with ROCE steady at 14.3%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Alembic Pharmaceuticals earn on its capital? Alembic Pharmaceuticals Ltd earned a ROCE of 13% in FY26. That is up from a low of 7% in FY23. Its return on capital used (ROIC) is 1.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 9.1% net margin and 0.84× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 9.1% net margin × 0.84× asset turnover × 1.54× leverage (assets divided by equity) ≈ 11.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 13.4% − 12.0% = +1.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 13.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Alembic Pharmaceuticals have too much debt? Alembic Pharmaceuticals Ltd has total debt of ₹1,430 Cr against shareholder equity of ₹5,669 Cr as of Jun 2026, so its debt is 0.25× its equity, which is very little. Year by year, that ratio went from 0.14 in FY22 to 0.25 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Alembic Pharmaceuticals shareholding pattern? No group of Alembic Pharmaceuticals Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved −0.6 points over the same period, to 15.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +0.6 points over 8 quarters, to 4.5%; Domestic institutions: −0.6 points over 8 quarters, to 15.4%; Promoters: +0.3 points over 8 quarters, to 69.9%. ## How far is Alembic Pharmaceuticals from balance-sheet trouble? For Alembic Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Alembic Pharmaceuticals rank in its industry? 47.9 out of 100, rank 23 of 44 in Pharma - Formulators, with 81% of the evidence available. Alembic Pharmaceuticals Ltd scores 47.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 23. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 15.2 + 10.7 + 11.7 + 10.3 = 47.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alembic Pharmaceuticals compared with? Alembic Pharmaceuticals ranks 23 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 47.9 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. Alembic Pharmaceuticals Ltd this page APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 14.1% · Profit 14.6% · Operating margin change -1 points · 88% evidence Capital efficiency 10.7/25 · ROCE 12.6% · Operating margin 15% · 100% evidence Valuation 11.7/20 · P/E 21× · PEG 1.74 · 100% evidence Relative strength 10.3/20 · Lead over its industry n/a · Lead over NIFTY 500 5.5% · 1 year -11.1% · 25% evidence · 7 of 12 weeks ahead Exact sum: 15.2 + 10.7 + 11.7 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 24. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Alembic Pharmaceuticals in size? Alembic Pharmaceuticals is the 20th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Rubicon Research, Caplin Point Laboratories and ERIS Lifesciences. Just below it: Natco Pharma, Marksans Pharma and Corona Remedies. ### Pharma - Formulators companies close in size

1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) ₹26,660 crore
2. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) ₹17,677 crore
3. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ₹16,044 crore
4. Alembic Pharmaceuticals Ltd ₹15,683 crore
5. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) ₹15,348 crore
6. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) ₹13,876 crore
7. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) ₹13,147 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) ₹15,728 crore · Pesticides/Agrochemicals
2. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) ₹15,703 crore · FMCG - Personal Care
3. Alembic Pharmaceuticals Ltd ₹15,683 crore
4. [Sarda Energy & Minerals Ltd](https://www.sectoralpha.in/stocks/sarda-energy-minerals-ltd) ₹15,535 crore · Mining/Minerals - Iron Ore
5. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) ₹15,480 crore · Chemicals - Organic

## What else do people ask about Alembic Pharmaceuticals? ### What is Alembic Pharmaceuticals's share price today? Alembic Pharmaceuticals Ltd's share price is ₹906.70, −1.7% over the past year. The whole company is worth ₹17,819 Cr on the market. In the last 52 weeks it traded between ₹656 to ₹922; today it is 94% of the way up from the low, 11.8% above its 200-day average (as of 4 November 2026). ### What were Alembic Pharmaceuticals's latest quarterly results? Alembic Pharmaceuticals Ltd reported revenue of ₹2,150 Cr and net profit of ₹172 Cr for the Jun 2026 quarter. Revenue rose 25.7% and profit rose 11.7% compared with a year earlier. Earnings per share were ₹8.80. The operating margin was 15.0%, 1.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Alembic Pharmaceuticals's market cap? Alembic Pharmaceuticals Ltd's market capitalisation is ₹17,819 Cr at a share price of ₹906.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Alembic Pharmaceuticals performing? Alembic Pharmaceuticals Ltd's share price has been stalling near its high for 3 weeks. In its latest quarter, revenue rose 25.7% and profit rose 11.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 23 weeks running (as of 4 November 2026). ### Will Alembic Pharmaceuticals's share price go up? This page does not forecast Alembic Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹906.70, and it has been stalling near its high for 3 weeks. Its P/E of 23.9× is higher than 51% of its own last 11 years (as of 4 November 2026). ### Does Alembic Pharmaceuticals have too much debt? No, Alembic Pharmaceuticals Ltd has little debt: its debt is 0.25× its equity, and its operating profit is 12 times its interest bill. FY26 borrowings were ₹1,430 Cr against equity of ₹5,675 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Alembic Pharmaceuticals in its business cycle? Alembic Pharmaceuticals Ltd's FY26 operating margin was 15.0%, against a 13-year range of 12.0% to 32.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 15.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Alembic Pharmaceuticals story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Alembic Pharmaceuticals a stock worth studying right now? What the numbers show: Alembic Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +15.7% in a year while the price moved −1.7%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.